Hillstream Competitors

Delisted . USA . 
Stock . Hillstream Biopharma
HILSDelisted Stock  USD 0.39  0.01  2.50%   
Hillstream Biopharma competes with Virax Biolabs, Revelation Biosciences, Kiora Pharmaceuticals, ZyVersa Therapeutics, and Palisade Bio; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Hillstream Biopharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Hillstream Biopharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Hillstream Biopharma competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.390.390.39
Details
Intrinsic
Valuation
LowRealHigh
0.370.370.43
Details
Naive
Forecast
LowNextHigh
0.370.370.37
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.340.380.42
Details

Hillstream Biopharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Hillstream Biopharma and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Hillstream and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Hillstream Biopharma does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
IMMX
+ 0.89
VRAX
REVB
+ 0.84
VRAX
PALI
+ 0.81
ZVSA
IMMX
+ 0.75
REVB
ZVSA
+ 0.6
VRAX
UNCY
+ 0.54
BWV
  
High negative correlations   
UNCY
- 0.78
ZVSA
UNCY
- 0.72
PALI
UNCY
- 0.5
VRAX
APGN
- 0.43
BWV
UNCY
- 0.37
REVB
ZVSA
- 0.35
BWV

Risk-Adjusted Indicators

There is a big difference between Hillstream Stock performing well and Hillstream Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Hillstream Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Hillstream Biopharma Competitive Analysis

The better you understand Hillstream Biopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Hillstream Biopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Hillstream Biopharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
HILS VRAX BWV REVB KPRX ZVSA PALI UNCY APGN IMMX
 2.50 
 0.39 
Hillstream
 4.98 
 2.11 
Virax
 3.45 
 1.12 
BWV
 2.63 
 0.74 
Revelation
 1.48 
 3.32 
Kiora
 1.77 
 1.11 
ZyVersa
 1.64 
 2.40 
Palisade
 3.77 
 0.55 
Unicycive
 2.27 
 0.43 
Apexigen
 3.91 
 1.72 
Immix
Market Volatility
(90 Days Market Risk)
Very steady
Risky
Very steady
Very risky
Slightly risky
Abnormally volatile
Relatively risky
Extremely Dangerous
Very steady
Risky
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
OK
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Low
Dangerous
Very High
Low
Average
Very High
Low
Dangerous
Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Sell
Not Available
Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Not Available
Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Not Rated
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Not Rated
Strong Sell
Current Ratio
13.13
0.04
7.69
0.68
1.53
N/A
2.59
4.43
1.24
19.53
Net Asset
6.69 M
5.48 M
26.31 M
12.21 M
13.71 M
22.11 M
14.05 M
14.19 M
22.86 M
19.93 M
Profit Margin
N/A
N/A
N/A
N/A
0.2
N/A
N/A
N/A
N/A
N/A
EBITDA
(6.88 M)
(6.61 M)
(13.54 M)
(95.21 K)
(12.35 M)
(107.74 M)
(12.28 M)
(30.18 M)
(32.58 M)
(16.14 M)
Current Valuation
496.66 K
5.36 M
8.81 M
9.46 M
(18.85 M)
(480.08 K)
(3.95 M)
23.47 M
205.33 K
30.64 M
Price To Book
0.88
1.63
0.35
1.21
0.34
0.38
0.56
1.98
2.32
2.81
Operating Margin
N/A
-42.54
N/A
N/A
-121.23
N/A
N/A
N/A
N/A
N/A
Retained Earnings
(15.38 M)
(18.53 M)
(19.38 M)
(25.47 M)
(146.98 M)
(103.22 M)
(121.51 M)
(64.54 M)
(176.79 M)
(53.41 M)
Five Year Return
N/A
N/A
7.08
N/A
N/A
N/A
N/A
N/A
N/A
N/A
One Year Return
N/A
N/A
4.21
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
N/A
1.93
N/A
0.15
-0.29
0.64
1.33
2.29
3.62
0.1
Number Of Employees
1
17
12
9
12
7
9
14
11
14
Shares Outstanding
17.53 M
4.34 M
18.66 M
4.29 M
2.97 M
2.34 M
1.33 M
103.8 M
24.86 M
27.51 M
Three Year Return
N/A
N/A
6.32
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash Flow From Operations
(6.56 M)
(6.25 M)
(8.7 M)
(7.29 M)
(9.56 M)
(8.72 M)
(11.13 M)
(18.28 M)
(30.69 M)
(11.37 M)
Total Debt
772.9 K
224.3 K
N/A
5.56 M
106.89 K
8.66 K
369 K
811 K
106 K
3.72 M
Return On Equity
-1.47
-0.96
-1.02
-2.7
0.14
-1.52
-1.1
-1.22
-15.98
-1.04
Z Score
-2.34
N/A
-1.71
N/A
N/A
N/A
N/A
N/A
38.91
N/A
Return On Asset
-0.78
-0.5
-0.3
-0.51
0.13
-0.25
-0.59
-0.53
-0.89
-0.57
Number Of Shares Shorted
52.74 K
446.54 K
23.33 K
41.24 K
46.67 K
45.48 K
43.11 K
1.05 M
64.45 K
434.94 K
Book Value Per Share
0.18
2.09
0.57
0.62
7.14
27.33
18.3
-0.11
-0.093
0.82
Total Asset
6.69 M
5.48 M
26.31 M
12.21 M
13.71 M
22.11 M
14.05 M
14.19 M
22.86 M
19.93 M
Short Ratio
0.2
0.11
0.13
0.69
0.27
0.19
0.29
0.74
1.72
2.94
Target Price
4.0
20.0
9.0
12.75
30.33
20.0
30.33
5.5
0.64
7.0
Debt To Equity
N/A
N/A
N/A
0.009
0.018
N/A
0.23
0.023
0.054
0.002
Shares Owned By Institutions
0.8
5.37
23.44
2.31
48.34
4.47
3.57
38.2
13.54
17.64
Market Capitalization
4.23 M
8.73 M
3.54 M
3.24 M
10.75 M
2.65 M
3.73 M
55.01 M
9.57 M
49.24 M
Price To Earning
N/A
N/A
N/A
8.69
N/A
N/A
0.16
N/A
N/A
N/A
Price To Sales
N/A
55.79
N/A
2.88
0.63
N/A
14.03
62.82
N/A
N/A
Net Income
(8.47 M)
(6.74 M)
(13.42 M)
(120.25 K)
(12.51 M)
(98.3 M)
(12.3 M)
(30.54 M)
(32.07 M)
(15.6 M)
Earnings Per Share
-0.76
-3.36
-1.08
-17.53
16.53
491.97
-13.26
-0.46
-1.71
-0.84
Shares Owned By Insiders
38.9
7.06
17.69
0.12
2.3
0.61
1.88
6.73
8.81
40.09
Revenue
N/A
156.42 K
N/A
N/A
N/A
N/A
250 K
675 K
N/A
N/A
Working Capital
5.54 M
4.21 M
22.34 M
6.58 M
3.1 M
(6.84 M)
10.74 M
(4.13 M)
4.73 M
16.07 M
Ten Year Return
N/A
N/A
4.85
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
9.48 M
21.76 K
22.24 M
3.48 M
2.43 M
N/A
5 M
10.57 M
21.62 M
18.4 M
Cash Per Share
0.82
N/A
1.64
0.15
2.64
N/A
0.23
0.7
1.01
1.32
Gross Profit
N/A
(1.36 K)
N/A
90.91 M
(5.14 M)
N/A
N/A
N/A
N/A
N/A
Day Typical Price
0.39
2.11
1.14
0.75
3.35
1.12
2.44
0.55
0.44
1.77
Accumulation Distribution
0.0976
7968.7
0.0588
4657.21
139.91
2368.25
2471.64
69505.45
0.11
25794.38
Market Facilitation Index
0.04
0.0
0.07
N/A
0.0
0.0
0.0
N/A
0.05
0.0
Daily Balance Of Power
(0.25)
0.7692
(0.57)
(1.00)
(0.50)
(0.50)
(0.21)
0.6667
(0.20)
(0.39)
Period Momentum Indicator
(0.01)
0.1
(0.04)
(0.02)
(0.05)
(0.02)
(0.04)
0.02
(0.01)
(0.07)
Rate Of Daily Change
0.98
1.05
0.97
0.97
0.99
0.98
0.98
1.04
0.98
0.96
Day Median Price
0.39
2.12
1.16
0.75
3.36
1.12
2.46
0.55
0.44
1.8
Price Action Indicator
(0.01)
0.045
(0.06)
(0.02)
(0.07)
(0.02)
(0.07)
0.015
(0.02)
(0.11)
Relative Strength Index
52.36
47.84
54.91
48.39
49.86
34.7
28.12
71.24
40.98
59.42
Coefficient Of Variation
(1,956)
(895.86)
2678.15
(963.18)
(4,457)
(726.16)
(1,046)
830.61
8455.47
(3,182)
Mean Deviation
5.56
5.89
3.18
3.66
2.69
4.13
3.52
4.0
5.12
3.87
Jensen Alpha
(0.39)
(1.00)
0.3146
(0.84)
(0.17)
(0.89)
(0.37)
0.4306
0.2679
(0.35)
Total Risk Alpha
(2.32)
(2.52)
(1.00)
(1.51)
(0.65)
(2.43)
(1.25)
(0.21)
(1.29)
(1.05)
Sortino Ratio
N/A
N/A
0.0496
N/A
N/A
N/A
N/A
0.0884
(0)
N/A
Downside Variance
N/A
N/A
12.68
N/A
N/A
N/A
N/A
33.52
43.89
N/A
Standard Deviation
11.05
9.32
8.23
5.75
3.55
8.21
4.88
5.34
8.75
5.53
Kurtosis
20.41
13.19
50.36
7.74
0.9952
15.54
3.24
1.46
12.89
3.86
Potential Upside
8.33
9.65
4.26
8.97
5.95
7.57
5.97
9.76
7.89
7.06
Treynor Ratio
0.3817
2.77
(2.07)
(0.31)
(0.14)
0.5416
0.5468
0.3782
(0.06)
(0.14)
Maximum Drawdown
113.15
61.28
68.28
34.52
16.59
78.93
24.25
29.22
58.79
32.68
Variance
122.17
86.79
67.7
33.01
12.6
67.32
23.84
28.49
76.64
30.55
Market Risk Adjusted Performance
0.3917
2.78
(2.06)
(0.30)
(0.13)
0.5516
0.5568
0.3882
(0.05)
(0.13)
Risk Adjusted Performance
(0.03)
(0.08)
0.0377
(0.07)
(0.01)
(0.1)
(0.06)
0.1009
0.0182
(0.02)
Skewness
(0.58)
2.57
6.62
1.82
0.2923
0.3919
0.5199
0.5903
2.85
1.25
Semi Deviation
N/A
N/A
2.98
N/A
N/A
N/A
N/A
4.24
5.5
N/A
Information Ratio
(0.06)
(0.13)
0.0214
(0.13)
(0.06)
(0.15)
(0.12)
0.0959
(0)
(0.06)
Value At Risk
(7.89)
(12.97)
(4.72)
(7.83)
(4.97)
(9.60)
(8.55)
(7.41)
(11.11)
(8.22)
Expected Short fall
N/A
N/A
(5.30)
N/A
N/A
N/A
N/A
(5.20)
(7.45)
N/A
Downside Deviation
N/A
N/A
3.56
N/A
N/A
N/A
N/A
5.79
6.62
N/A
Semi Variance
N/A
N/A
8.91
N/A
N/A
N/A
N/A
17.96
30.2
N/A

Hillstream Biopharma Competition Performance Charts

Five steps to successful analysis of Hillstream Biopharma Competition

Hillstream Biopharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Hillstream Biopharma in relation to its competition. Hillstream Biopharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Hillstream Biopharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Hillstream Biopharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Hillstream Biopharma, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Hillstream Biopharma position

In addition to having Hillstream Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Military Industrial Thematic Idea Now

Military Industrial
Military Industrial Theme
A collection of large United States defense contractors including companies involved in production or distribution of aircraft, ships, vehicles, weaponry, and electronic systems in cooperation with the government. The Military Industrial theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Military Industrial Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Other Consideration for investing in Hillstream Stock

If you are still planning to invest in Hillstream Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hillstream Biopharma's history and understand the potential risks before investing.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY